John L Wallace

List of Publications by Year
in descending order

243 papers	25,257 citations	5876 81 h-index	7333 152 g-index
245 all docs	245 docs citations	245 times ranked	17308 citing authors

#	Article	IF	Citations
1	Hapten-Induced Model of Chronic Inflammation and Ulceration in the Rat Colon. Gastroenterology, 1989, 96, 795-803.	0.6	1,459
2	Resolution of in flammation: state of the art, definitions and terms. FASEB Journal, 2007, 21, 325-332.	0.2	949
3	Hydrogen sulfide is an endogenous modulator of leukocyteâ€mediated inflammation. FASEB Journal, 2006, 20, 2118-2120.	0.2	765
4	Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology, 1989, 96, 795-803.	0.6	694
5	Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. Nature Reviews Drug Discovery, 2015, 14, 329-345.	21.5	652
6	NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology, 2000, 119, 706-714.	0.6	630
7	Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself?. Physiological Reviews, 2008, 88, 1547-1565.	13.1	543
8	Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood, 2002, 100, 1160-1167.	0.6	528
9	Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology, 1989, 96, 29-36.	0.6	404
10	Proton Pump Inhibitors Exacerbate NSAID-Induced Small Intestinal Injury by Inducing Dysbiosis. Gastroenterology, 2011, 141, 1314-1322.e5.	0.6	387
11	Inhibition of Hydrogen Sulfide Generation Contributes to Gastric Injury Caused by Anti-Inflammatory Nonsteroidal Drugs. Gastroenterology, 2005, 129, 1210-1224.	0.6	367
12	Nitric oxide in mucosal defense: A little goes a long way. Gastroenterology, 2000, 119, 512-520.	0.6	365
13	Protease-activated receptors in inflammation, neuronal signaling and pain. Trends in Pharmacological Sciences, 2001, 22, 146-152.	4.0	361
14	Microglial Activation and Î²-Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice. Journal of Neuroscience, 2002, 22, 2246-2254.	1.7	358
15	The Emerging Roles of Hydrogen Sulfide in the Gastrointestinal Tract and Liver. Gastroenterology, 2006, 131, 259-271.	0.6	343
16	Induction of Intestinal Inflammation in Mouse by Activation of Proteinase-Activated Receptor-2. American Journal of Pathology, 2002, 161, 1903-1915.	1.9	342
17	The cellular and molecular basis of gastric mucosal defense. FASEB Journal, 1996, 10, 731-740.	0.2	302
18	Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: Implications for gastrointestinal toxicity. Gastroenterology, 1998, 115, 101-109.	0.6	297

#	Article	IF	Citations
19	Hydrogen sulfide-releasing anti-inflammatory drugs. Trends in Pharmacological Sciences, 2007, 28, 501-505.	4.0	288
20	Novel nonsterodial anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology, 1994, 107, 173-179.	0.6	283
21	A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit. Gastroenterology, 1991, 100, 878-883.	0.6	271
22	Endogenous and Exogenous Hydrogen Sulfide Promotes Resolution of Colitis in Rats. Gastroenterology, 2009, 137, 569-578.e1.	0.6	263
23	Potent ulcerogenic actions of platelet-activating factor on the stomach. Nature, 1986, 319, 54-56.	13.7	253
24	Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 216-220.	3.3	248
25	Synthesis and Biological Effects of Hydrogen Sulfide (H₂S): Development of H₂S-Releasing Drugs as Pharmaceuticals. Journal of Medicinal Chemistry, 2010, 53, 6275-6286.	2.9	243
26	Gastrointestinal Safety and Anti-Inflammatory Effects of a Hydrogen Sulfideâ€“Releasing Diclofenac Derivative in the Rat. Gastroenterology, 2007, 132, 261-271.	0.6	239
27	Evidence That Hydrogen Sulfide Exerts Antinociceptive Effects in the Gastrointestinal Tract by Activating KATP Channels. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 325-335.	1.3	238
28	A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology, 1995, 109, 524-530.	0.6	223
29	Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. British Journal of Pharmacology, 1999, 127, 1083-1090.	2.7	209
30	Hydrogen sulfide enhances ulcer healing in rats. FASEB Journal, 2007, 21, 4070-4076.	0.2	206
31	Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sciences, 1989, 45, 1869-1876.	2.0	195
32	Markedly reduced toxicity of a hydrogen sulphideâ€releasing derivative of naproxen (ATBâ€346). British Journal of Pharmacology, 2010, 159, 1236-1246.	2.7	192
33	Hydrogen Sulfide: An Endogenous Mediator of Resolution of Inflammation and Injury. Antioxidants and Redox Signaling, 2012, 17, 58-67.	2.5	188
34	Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Gastroenterology, 1987, 93, 765-773.	0.6	181
35	Hydrogen Sulfide Protects from Colitis and Restores Intestinal Microbiota Biofilm and Mucus Production. Inflammatory Bowel Diseases, 2015, 21, 1006-1017.	0.9	150
36	A Â-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15736-15741.	3.3	148

#	Article	IF	Citations
37	Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis. Gastroenterology, 1992, 102, 18-27.	0.6	147
38	The therapeutic potential of NO-NSAIDs. Fundamental and Clinical Pharmacology, 2003, 17, 11-20.	1.0	147
39	A diclofenac derivative without ulcerogenic properties. European Journal of Pharmacology, 1994, 257, 249-255.	1.7	146
40	Cyclooxygenase-2-derived prostaglandin D₂is an early anti-inflammatory signal in experimental colitis. American Journal of Physiology - Renal Physiology, 2000, 279, G238-G244.	1.6	144
41	Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World Journal of Gastroenterology, 2013, 19, 1861.	1.4	143
42	Role of mucus in the repair of gastric epithelial damage in the rat. Gastroenterology, 1986, 91, 603-611.	0.6	141
43	Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2001, 15, 691-703.	1.0	140
44	Systematic study of constitutive cyclooxygenase-2 expression: Role of NF-ÎºB and NFAT transcriptional pathways. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 434-439.	3.3	140
45	Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. British Journal of Pharmacology, 2005, 145, 275-282.	2.7	134
46	Cyclooxygenase-2â€“derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology, 2002, 123, 1598-1606.	0.6	133
47	NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. British Journal of Pharmacology, 2012, 165, 67-74.	2.7	131
48	Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13243-13247.	3.3	130
49	Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11104-11109.	3.3	130
50	5-Amino-2-hydroxybenzoic Acid 4-(5-Thioxo-5H-[1,2]dithiol-3yl)-phenyl Ester (ATB-429), a Hydrogen Sulfide-Releasing Derivative of Mesalamine, Exerts Antinociceptive Effects in a Model of Postinflammatory Hypersensitivity. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 447-458.	1.3	130
51	Potential cardioprotective actions of no-releasing aspirin. Nature Reviews Drug Discovery, 2002, 1, 375-382.	21.5	129
52	Pathogenesis of NSAID gastropathy: are neutrophils the culprits?. Trends in Pharmacological Sciences, 1992, 13, 129-131.	4.0	126
53	Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanism. British Journal of Pharmacology, 2001, 133, 975-987.	2.7	125
54	Giardia duodenalis induces pathogenic dysbiosis of human intestinal microbiota biofilms. International Journal for Parasitology, 2017, 47, 311-326.	1.3	125

#	Article	IF	Citations
55	The roles of ethanol and of acid in the production of gastric mucosal erosions in rats. Vigiliae Christianae, 1981, 38, 23-38.	0.1	124
56	Gastrointestinal biofilms in health and disease. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 314-334.	8.2	124
57	Gastrointestinal Inflammation: A Central Component of Mucosal Defense and Repair. Experimental Biology and Medicine, 2006, 231, 130-137.	1.1	122
58	Anti-Inflammatory and Cytoprotective Actions of Hydrogen Sulfide: Translation to Therapeutics. Antioxidants and Redox Signaling, 2015, 22, 398-410.	2.5	120
59	Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10937-10941.	3.3	118
60	Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. British Journal of Pharmacology, 1999, 126, 1200-1204.	2.7	117
61	Prostaglandins inhibit inflammatory mediator release from rat mast cells. Gastroenterology, 1993, 104, 122-129.	0.6	116
62	Physiological and Pathophysiological Roles of Hydrogen Sulfide in the Gastrointestinal Tract. Antioxidants and Redox Signaling, 2010, 12, 1125-1133.	2.5	115
63	Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. British Journal of Pharmacology, 2000, 129, 1423-1430.	2.7	112
64	Pro- and anti-inflammatory actions of thrombin: a distinct role for proteinase-activated receptor-1 (PAR1). British Journal of Pharmacology, 1999, 126, 1262-1268.	2.7	111
65	Reduction by cytoprotective agents of ethanol-induced damage to the rat gastric mucosa: a correlated morphological and physiological study. Canadian Journal of Physiology and Pharmacology, 1982, 60, 1686-1699.	0.7	110
66	Nitric oxide as a regulator of inflammatory processes. Memorias Do Instituto Oswaldo Cruz, 2005, 100, 5-9.	0.8	107
67	Mechanisms of protection and healing: current knowledge and future research. American Journal of Medicine, 2001, 110, S19-S23.	0.6	106
68	Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor. British Journal of Pharmacology, 2000, 129, 681-686.	2.7	104
69	Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sciences, 1998, 62, 367-373.	2.0	103
70	Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. Gastroenterology, 1995, 109, 1173-1180.	0.6	97
71	Interactions of hydrogen sulfide with myeloperoxidase. British Journal of Pharmacology, 2015, 172, 1516-1532.	2.7	96
72	Hydrogen Sulfide-Releasing Therapeutics: Translation to the Clinic. Antioxidants and Redox Signaling, 2018, 28, 1533-1540.	2.5	96

#	Article	IF	Citations
73	Inflammatory Mediators in Gastrointestinal Defense and Injury. Experimental Biology and Medicine, 2001, 226, 1003-1015.	1.1	94
74	Hydrogen sulphide synthesis in the rat and mouse gastrointestinal tract. Digestive and Liver Disease, 2010, 42, 103-109.	0.4	93
75	The mucoid cap over superficial gastric damage in the rat. Gastroenterology, 1990, 99, 295-304.	0.6	92
76	PROSTAGLANDIAN BIOLOGY IN INFLAMMATORY BOWEL DISEASE. Gastroenterology Clinics of North America, 2001, 30, 971-980.	1.0	92
77	Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs). American Journal of Medicine, 1999, 107, 11-16.	0.6	91
78	Gaseous mediators in resolution of inflammation. Seminars in Immunology, 2015, 27, 227-233.	2.7	86
79	In Vivo Antithrombotic Effects of a Nitric Oxide-Releasing Aspirin Derivative, NCX-4016. Thrombosis Research, 1999, 93, 43-50.	0.8	85
80	Hydrogen sulfide: an agent of stability at the microbiome-mucosa interface. American Journal of Physiology - Renal Physiology, 2018, 314, G143-G149.	1.6	85
81	The 1994 Merck Frosst Award. Mechanisms of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damageâ€"potential for development of gastrointestinal tract safe NSAIDs. Canadian Journal of Physiology and Pharmacology, 1994, 72, 1493-1498.	0.7	83
82	Enhanced anti-inflammatory effects of a nitric oxideâ€"releasing derivative of mesalamine in rats. Gastroenterology, 1999, 117, 557-566.	0.6	83
83	Hapten-induced chronic colitis in the rat: Alternatives to trinitrobenzene sulfonic acid. Journal of Pharmacological and Toxicological Methods, 1995, 33, 237-239.	0.3	82
84	Hydrogen sulfide and resolution of acute inflammation: A comparative study utilizing a novel fluorescent probe. Scientific Reports, 2012, 2, 499.	1.6	82
85	A role for proteinase-activated receptorâ€"1 in inflammatory bowel diseases. Journal of Clinical Investigation, 2004, 114, 1444-1456.	3.9	82
86	Endothelial nitric oxide synthase modulates gastric ulcer healing in rats. American Journal of Physiology - Renal Physiology, 2000, 279, G341-G346.	1.6	81
87	Colitis induced by proteinase-activated receptor-2 agonists is mediated by a neurogenic mechanism. Canadian Journal of Physiology and Pharmacology, 2003, 81, 920-927.	0.7	81
88	COX-2: A Pivotal Enzyme in Mucosal Protection and Resolution of Inflammation. Scientific World Journal, The, 2006, 6, 577-588.	0.8	81
89	V. Therapeutic potential of nitric oxide donors and inhibitors. American Journal of Physiology - Renal Physiology, 1999, 276, G1313-G1316.	1.6	80
90	NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis. British Journal of Pharmacology, 2000, 130, 1399-1405.	2.7	80

#	Article	IF	Citations
91	How do NSAIDs cause ulcer disease?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2000, 14, 147-159.	1.0	80
92	Gastrointestinal-Sparing Effects of Novel NSAIDs in Rats with Compromised Mucosal Defence. PLoS ONE, 2012, 7, e35196.	1.1	80
93	Up-Regulation of Annexin-A1 and Lipoxin A4 in Individuals with Ulcerative Colitis May Promote Mucosal Homeostasis. PLoS ONE, 2012, 7, e39244.	1.1	80
94	Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatments. American Journal of Physiology - Renal Physiology, 2013, 305, G467-G473.	1.6	79
95	Impaired hydrogen sulfide synthesis and IL-10 signaling underlie hyperhomocysteinemia-associated exacerbation of colitis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13559-13564.	3.3	79
96	Nitric oxide: A regulator of mucosal defense and injury. Journal of Gastroenterology, 1998, 33, 792-803.	2.3	78
97	Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 1689-1694.	3.3	77
98	A pro-resolution mediator, prostaglandin D ₂ , is specifically up-regulated in individuals in long-term remission from ulcerative colitis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12023-12027.	3.3	77
99	Gastric ulceration: critical events at the neutrophilâ€“endothelium interface. Canadian Journal of Physiology and Pharmacology, 1993, 71, 98-102.	0.7	75
100	Selective COX-2 inhibitors: is the water becoming muddy?. Trends in Pharmacological Sciences, 1999, 20, 4-6.	4.0	75
101	H2S-releasing drugs: Anti-inflammatory, cytoprotective and chemopreventative potential. Nitric Oxide - Biology and Chemistry, 2015, 46, 25-31.	1.2	75
102	Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation, 1992, 16, 227-240.	1.7	74
103	Picomole doses of platelet-activating factor predispose the gastric mucosa to damage by topical irritants. Prostaglandins, 1986, 31, 989-998.	1.2	73
104	Release of platelet-activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis. Canadian Journal of Physiology and Pharmacology, 1988, 66, 422-425.	0.7	72
105	Tissue-selective inhibition of prostaglandin synthesis in rat by tepoxalin: Anti-inflammatory without gastropathy?. Gastroenterology, 1993, 105, 1630-1636.	0.6	72
106	A proofâ€ofâ€concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfideâ€releasing antiâ€inflammatory drug. British Journal of Pharmacology, 2020, 177, 769-777.	2.7	72
107	Effects of Leukotrienes on Susceptibility of the Rat Stomach to Damage and Investigation of the Mechanism of Action. Gastroenterology, 1990, 98, 1178-1186.	0.6	70
108	Effects of Chondroitin and Glucosamine Sulfate in a Dietary Bar Formulation on Inflammation, Interleukin-1Î², Matrix Metalloprotease-9, and Cartilage Damage in Arthritis. Experimental Biology and Medicine, 2005, 230, 255-262.	1.1	68

#	Article	IF	Citations
109	NSAID enteropathy and bacteria: a complicated relationship. Journal of Gastroenterology, 2015, 50, 387-393.	2.3	68
110	Prevention and reversal of experimental colitis by a monoclonal antibody which inhibits leukocyte adherence. Inflammation, 1992, 16, 343-354.	1.7	67
111	Role of prostanoids in the protective actions of BW755C on the gastric mucosa. European Journal of Pharmacology, 1985, 115, 45-52.	1.7	66
112	NSAID-gastroenteropathy: new aspects of pathogenesis and prevention. Current Opinion in Pharmacology, 2014, 19, 11-16.	1.7	66
113	Persistent epithelial dysfunction and bacterial translocation after resolution of intestinal inflammation. American Journal of Physiology - Renal Physiology, 2001, 281, G635-G644.	1.6	65
114	ATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo. Pharmacological Research, 2016, 114, 67-73.	3.1	65
115	Hydrogen sulfide inhibits oxidative stress in lungs from allergic mice in vivo. European Journal of Pharmacology, 2013, 698, 463-469.	1.7	64
116	Relative contribution of acetylated cyclooxygenase (COX)â€2 and 5â€lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB Journal, 2003, 17, 1171-1173.	0.2	63
117	Recent advances in gastric ulcer therapeutics. Current Opinion in Pharmacology, 2005, 5, 573-577.	1.7	63
118	Proteinase-Activated Receptor (PAR)-1 and -2 Agonists Induce Mediator Release from Mast Cells by Pathways Distinct from PAR-1 and PAR-2. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 466-474.	1.3	62
119	Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis. Trends in Pharmacological Sciences, 2009, 30, 112-117.	4.0	62
120	Prevention of endotoxin-induced gastrointestinal damage by CV-3988, an antagonist of platelet-activating factor. European Journal of Pharmacology, 1986, 124, 209-210.	1.7	61
121	Bacteria rapidly colonize and modulate healing of gastric ulcers in rats. American Journal of Physiology - Renal Physiology, 1998, 275, G425-G432.	1.6	61
122	Enhanced Synthesis and Diminished Degradation of Hydrogen Sulfide in Experimental Colitis: A Site-Specific, Pro-Resolution Mechanism. PLoS ONE, 2013, 8, e71962.	1.1	61
123	Neutrophil-Mediated Gastrointestinal Injury. Canadian Journal of Gastroenterology & Hepatology, 1998, 12, 559-568.	1.8	60
124	Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Life Sciences, 1998, 62, PL235-PL240.	2.0	58
125	Prolonged colonic epithelial hyporesponsiveness after colitis: role of inducible nitric oxide synthase. American Journal of Physiology - Renal Physiology, 1999, 276, G703-G710.	1.6	58
126	Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. British Journal of Pharmacology, 2001, 133, 1314-1322.	2.7	58

#	Article	IF	Citations
127	A magic bullet for mucosal protectionâ€¦and aspirin is the trigger!. Trends in Pharmacological Sciences, 2003, 24, 323-326.	4.0	58
128	Effects of Hydrogen Sulfide on the Microbiome: From Toxicity to Therapy. Antioxidants and Redox Signaling, 2022, 36, 211-219.	2.5	58
129	Nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: New insights into an old problem. Journal of Gastroenterology, 1997, 32, 127-133.	2.3	57
130	Eukaryotic and prokaryotic contributions to colonic hydrogen sulfide synthesis. American Journal of Physiology - Renal Physiology, 2011, 301, G188-G193.	1.6	56
131	Markedly reduced intestinal toxicity of a diclofenac derivative. Life Sciences, 1994, 55, PL1-PL8.	2.0	55
132	Acetaminophen hepatotoxicity: NO to the rescue. British Journal of Pharmacology, 2004, 143, 1-2.	2.7	53
133	Annexin-1 modulates repair of gastric mucosal injury. American Journal of Physiology - Renal Physiology, 2008, 294, G764-G769.	1.6	53
134	Hydrogen sulphide protects against <scp>NSAID</scp>â€enteropathy through modulation of bile and the microbiota. British Journal of Pharmacology, 2015, 172, 992-1004.	2.7	53
135	Nitric oxide as a mediator of gastrointestinal mucosal injury?â€”Say it ain't so. Mediators of Inflammation, 1995, 4, 397-405.	1.4	52
136	Proresolution effects of hydrogen sulfide during colitis are mediated through hypoxiaâ€inducible factorâ€1Î±. FASEB Journal, 2015, 29, 1591-1602.	0.2	52
137	Aspirin-Triggered, Cyclooxygenase-2â€“Dependent Lipoxin Synthesis Modulates Vascular Tone. Circulation, 2004, 110, 1320-1325.	1.6	51
138	Hydrogen sulfide-releasing cyclooxygenase inhibitor ATB-346 enhances motor function and reduces cortical lesion volume following traumatic brain injury in mice. Journal of Neuroinflammation, 2014, 11, 196.	3.1	51
139	Anti-inflammatory effect of ATB-352, a H2S â”releasing ketoprofen derivative, on lipopolysaccharide-induced periodontitis in rats. Pharmacological Research, 2018, 132, 220-231.	3.1	51
140	Leukotriene B4 potentiates colonic ulceration in the rat. Digestive Diseases and Sciences, 1990, 35, 622-629.	1.1	50
141	Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. American Journal of Physiology - Renal Physiology, 2004, 286, G76-G81.	1.6	50
142	Anti-inflammatory and Cytoprotective Properties of Hydrogen Sulfide. Methods in Enzymology, 2015, 555, 169-193.	0.4	49
143	Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist. British Journal of Pharmacology, 2001, 134, 701-704.	2.7	48
144	Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. American Journal of Physiology - Renal Physiology, 2003, 285, G54-G61.	1.6	47

#	Article	IF	Citations
145	Mechanisms of Nonsteroidal Anti-Inflammatory Drug-Induced Gastrointestinal Injury and Repair: A Window of Opportunity for Cyclooxygenase-Inhibiting Nitric Oxide Donors. Canadian Journal of Gastroenterology & Hepatology, 2004, 18, 229-236.	1.8	46
146	Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer. Nitric Oxide - Biology and Chemistry, 2014, 41, 131-137.	1.2	46
147	Eicosanoids in the gastrointestinal tract. British Journal of Pharmacology, 2019, 176, 1000-1008.	2.7	46
148	Selective Inhibitors of Cyclooxygenase-2: Are They Really Effective, Selective, and GI-safe?. Journal of Clinical Gastroenterology, 1998, 27, S28-S34.	1.1	45
149	Endogenous Prostaglandins and Afferent Sensory Nerves in Gastroprotective Effect of Hydrogen Sulfide against Stress-Induced Gastric Lesions. PLoS ONE, 2015, 10, e0118972.	1.1	45
150	Impaired vasodilatory responses in the gastric microcirculation of anesthetized rats with secondary biliary cirrhosis. Gastroenterology, 1995, 108, 1183-1191.	0.6	44
151	Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative: role of neutrophils. American Journal of Physiology - Renal Physiology, 1997, 273, G1246-G1251.	1.6	44
152	Gaseous Mediators in Gastrointestinal Mucosal Defense and Injury. Digestive Diseases and Sciences, 2017, 62, 2223-2230.	1.1	44
153	<scp>Nitric oxide</scp> in the gastrointestinal tract: opportunities for drug development. British Journal of Pharmacology, 2019, 176, 147-154.	2.7	44
154	Mechanisms underlying the protective effects of interleukin 1 in experimental nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology, 1992, 102, 1176-1185.	0.6	43
155	Cooperation between Aspirin-Triggered Lipoxin and Nitric Oxide (NO) Mediates Antiadhesive Properties of 2-(Acetyloxy)benzoic Acid 3-(Nitrooxymethyl)phenyl Ester (NCX-4016) (NO-Aspirin) on Neutrophil-Endothelial Cell Adherence. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 1174-1182.	1.3	42
156	Deciphering the pathogenesis of NSAID enteropathy using proton pump inhibitors and a hydrogen sulfide-releasing NSAID. American Journal of Physiology - Renal Physiology, 2015, 308, G994-G1003.	1.6	41
157	Polypharmacy of Osteoarthritis: The Perfect Intestinal Storm. Digestive Diseases and Sciences, 2013, 58, 3088-3093.	1.1	40
158	NSAID-induced gastrointestinal damage and the design of GI-sparing NSAIDs. Current Opinion in Investigational Drugs, 2008, 9, 1151-6.	2.3	40
159	Reduction of the severity of experimental gastric and duodenal ulceration by interleukin-1Î². European Journal of Pharmacology, 1990, 186, 279-284.	1.7	39
160	Reduction of gastrointestinal injury in acute endotoxic shock by flurbiprofen nitroxybutylester. European Journal of Pharmacology, 1995, 280, 63-68.	1.7	39
161	Predisposition to Colorectal Cancer in Rats with Resolved Colitis. American Journal of Pathology, 2005, 167, 1293-1300.	1.9	39
162	Nitric Oxide, Aspirin-Triggered Lipoxins and NO-Aspirin in Gastric Protection. Inflammation and Allergy: Drug Targets, 2006, 5, 133-137.	1.8	39

#	Article	IF	Citations
163	Active thrombin produced by the intestinal epithelium controls mucosal biofilms. Nature Communications, 2019, 10, 3224.	5.8	39
164	Effects of inhibitors of arachidonic acid metabolism on Pafâ€induced gastric mucosal necrosis and haemoconcentration. British Journal of Pharmacology, 1986, 89, 415-422.	2.7	38
165	Sildenafil prevents indomethacin-induced gastropathy in rats: role of leukocyte adherence and gastric blood flow. British Journal of Pharmacology, 2005, 146, 481-486.	2.7	38
166	Platelets accelerate gastric ulcer healing through presentation of vascular endothelial growth factor. British Journal of Pharmacology, 2006, 148, 274-278.	2.7	38
167	Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. British Journal of Pharmacology, 2004, 143, 618-625.	2.7	37
168	Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H528-H535.	1.5	35
169	A hydrogen sulfideâ€releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury. FASEB Journal, 2013, 27, 4489-4499.	0.2	35
170	Role of cyclooxygenase-2 in modulating gastric acid secretion in the normal and inflamed rat stomach. American Journal of Physiology - Renal Physiology, 2000, 279, G1292-G1297.	1.6	34
171	Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. British Journal of Pharmacology, 2002, 135, 1540-1546.	2.7	33
172	A vascular endothelial growth factor mimetic accelerates gastric ulcer healing in an iNOS-dependent manner. American Journal of Physiology - Renal Physiology, 2008, 295, G374-G381.	1.6	33
173	Gastric Tolerability and Prolonged Prostaglandin Inhibition in the Brain with a Nitric Oxide-Releasing Flurbiprofen Derivative, NCX-2216 [3-[4-(2-Fluoro-Î±-methyl-[1,1â€²-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl ester]. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 626-633.	1.3	32
174	A comparative study on the anti-inflammatory effects of single oral doses of naproxen and its hydrogen sulfide (H2S)-releasing derivative ATB-346 in rats with carrageenan-induced synovitis. Medical Gas Research, 2013, 3, 24.	1.2	32
175	Gastrointestinal-sparing anti-inflammatory drugs: The development of nitric oxide-releasing NSAIDs. , 1997, 42, 144-149.		31
176	Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF-Î± release. American Journal of Physiology - Renal Physiology, 1999, 277, G847-G854.	1.6	31
177	A NO-releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway â€THIS ARTICLE HAS BEEN RETRACTED. British Journal of Pharmacology, 2002, 135, 589-599.	2.7	31
178	Inhibition of Neurogenic Inflammation by the Amazonian Herbal Medicine Sangre de Grado. Journal of Investigative Dermatology, 2001, 117, 725-730.	0.3	30
179	Iron Sequestration in Microbiota Biofilms As A Novel Strategy for Treating Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 1493-1502.	0.9	30
180	Cytoprotective Effects of Hydrogen Sulfide in Novel Rat Models of Non-Erosive Esophagitis. PLoS ONE, 2014, 9, e110688.	1.1	30

#	Article	IF	Citations
181	Mucosal Repair and COX-2 Inhibition. Current Pharmaceutical Design, 2003, 9, 2207-2211.	0.9	29
182	Underlying Mechanisms of Portal Hypertensive Gastropathy. Journal of Clinical Gastroenterology, 1997, 25, S73-S78.	1.1	27
183	Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H2004-H2010.	1.5	26
184	Characterization of a simple animal model for nonsteroidal anti-inflammatory drug induced antral ulcer. Canadian Journal of Physiology and Pharmacology, 1993, 71, 447-452.	0.7	25
185	Hydrogen sulfide-releasing anti-inflammatory drugs for chemoprevention and treatment of cancer. Pharmacological Research, 2016, 111, 652-658.	3.1	25
186	Enhanced Analgesic Effects and Gastrointestinal Safety of a Novel, Hydrogen Sulfide-Releasing Anti-Inflammatory Drug (ATB-352): A Role for Endogenous Cannabinoids. Antioxidants and Redox Signaling, 2020, 33, 1003-1009.	2.5	25
187	Enhanced anti-inflammatory potency of a nitric oxide-releasing prednisolone derivative in the rat. British Journal of Pharmacology, 2003, 139, 966-972.	2.7	24
188	Hydrogen Sulfide: A Rescue Molecule for Mucosal Defence and Repair. Digestive Diseases and Sciences, 2012, 57, 1432-1434.	1.1	22
189	Prevention of NSAID-Enteropathy: A Soluble Problem?. Digestive Diseases and Sciences, 2016, 61, 1-3.	1.1	22
190	Giardia spp. promote the production of antimicrobial peptides and attenuate disease severity induced by attaching and effacing enteropathogens via the induction of the NLRP3 inflammasome. International Journal for Parasitology, 2020, 50, 263-275.	1.3	22
191	Roles of Platelets and Proteinase-Activated Receptors in Gastric Ulcer Healing. Digestive Diseases and Sciences, 2005, 50, S12-S15.	1.1	21
192	Profound Chemopreventative Effects of a Hydrogen Sulfide-Releasing NSAID in the APCMin/+ Mouse Model of Intestinal Tumorigenesis. PLoS ONE, 2016, 11, e0147289.	1.1	21
193	A protease activated receptor-2 (PAR-2) activating peptide, tc-LIGRLO-NH2, induces protease release from mast cells: role in TNF degradation. BMC Pharmacology, 2004, 4, 12.	0.4	20
194	New Pharmacologic Therapies in Gastrointestinal Disease. Gastroenterology Clinics of North America, 2010, 39, 709-720.	1.0	20
195	Muc-2â€“Deficient Mice Display a Sex-Specific, COX-2â€“Related Impairment of Gastric Mucosal Repair. American Journal of Pathology, 2011, 178, 1126-1133.	1.9	20
196	Effects of conventional and hydrogen sulfide-releasing non-steroidal anti-inflammatory drugs in rats with stress-induced and epinephrine-induced gastric damage. Stress, 2014, 17, 528-537.	0.8	19
197	Increased Mucosal Thrombin is Associated with Crohnâ€™s Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation. Journal of Crohn's and Colitis, 2021, 15, 787-799.	0.6	19
198	Nitric Oxide-Releasing Nsaids: a Novel Class of Gi-Sparing Anti-Inflammatory Drugs. , 1995, 46, 121-129.		19

#	Article	IF	Citations
199	Acceleration of recovery of gastric epithelial integrity by 16,16â€dimethyl prostaglandin E₂. British Journal of Pharmacology, 1985, 86, 837-842.	2.7	18
200	Failure of prostaglandin E₂ and its 16,16â€dimethyl analogue to prevent the gastric mucosal damage induced by Paf. British Journal of Pharmacology, 1987, 90, 365-371.	2.7	18
201	Enhanced Anti-Inflammatory Potency of a Nitric Oxide-Releasing Derivative of Flunisolide: Role of Nuclear Factor-ÎºB. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 1096-1102.	1.3	18
202	Inhibition of Attaching and Effacing Lesion Formation following Enteropathogenic Escherichia coli and Shiga Toxin-Producing E. coli Infection. Infection and Immunity, 2001, 69, 7152-7158.	1.0	17
203	Environmental and NSAID-Enteropathy: Dysbiosis as a Common Factor. Current Gastroenterology Reports, 2014, 16, 377.	1.1	17
204	Gaseous mediator-based anti-inflammatory drugs. Current Opinion in Pharmacology, 2015, 25, 1-6.	1.7	17
205	Gaseous Mediators as a Key Molecular Targets for the Development of Gastrointestinal-Safe Anti-Inflammatory Pharmacology. Frontiers in Pharmacology, 2021, 12, 657457.	1.6	16
206	NO-mesalamine protects colonic epithelial cells against apoptotic damage induced by proinflammatory cytokines. American Journal of Physiology - Renal Physiology, 2001, 281, G654-G665.	1.6	15
207	Gastrointestinal damage induced by platelet-activating factor. Digestive Diseases and Sciences, 1988, 33, 225-232.	1.1	14
208	Selective Inhibitors of Cyclooxygenase-2. Drugs and Aging, 1996, 9, 406-417.	1.3	13
209	Annexin-1 is an endogenous gastroprotective factor against indomethacin-induced damage. American Journal of Physiology - Renal Physiology, 2005, 288, G481-G486.	1.6	13
210	Lipoxins in gastric mucosal health & disease. Prostaglandins Leukotrienes and Essential Fatty Acids, 2005, 73, 251-255.	1.0	13
211	Hydrogen Sulfide-Based Anti-Inflammatory and Chemopreventive Therapies: An Experimental Approach. Current Pharmaceutical Design, 2015, 21, 3012-3022.	0.9	13
212	Immunopathology of NSAID-Gastropathy: Inhibitory Effectsn of Interleukin-I and Cyclosporin A. Annals of the New York Academy of Sciences, 1992, 664, 400-407.	1.8	12
213	Commonality of Defensive Roles of COX-2 in the Lung and Gut. American Journal of Pathology, 2006, 168, 1060-1063.	1.9	11
214	Pathogenesis of Nonsteroidal Anti-Inflammatory Drug Gastropathy: Clues to Preventative Therapy. Canadian Journal of Gastroenterology & Hepatology, 1999, 13, 123-127.	1.8	10
215	Microbiome Profile and Molecular Pathways Alterations in Gastrointestinal Tract by Hydrogen Sulfide-Releasing Nonsteroidal Anti-Inflammatory Drug (ATB-352): Insight into Possible Safer Polypharmacy. Antioxidants and Redox Signaling, 2022, 36, 189-210.	2.5	8
216	Synthesis and Analgesic Activity of 2-Methyl-2-[1-(3-benzoyl-4-substituted-1,4-dihydropyridyl)]acetic Acid Methyl Esters, Acetic Acids, and Acetamides. Archiv Der Pharmazie, 1999, 332, 213-218.	2.1	7

#	Article	IF	Citations
217	Alterations in regional blood flow in rats following sensitization to the nematode Nippostrongylus brasiliensis: effects of PAF antagonists. British Journal of Pharmacology, 1990, 101, 93-96.	2.7	6
218	Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H3636-H3642.	1.5	6
219	Su1724 Bifidobacteria Exert a Protective Effect Against NSAID-Induced Enteropathy That is Dependent on Lactate Production. Gastroenterology, 2012, 142, S-489.	0.6	6
220	Toward More GI-Friendly Anti-Inflammatory Medications. Current Treatment Options in Gastroenterology, 2015, 13, 377-385.	0.3	6
221	Exposure to non-steroid anti-inflammatory drugs (NSAIDs) and suppressing hydrogen sulfide synthesis leads to altered structure and impaired function of the oesophagus and oesophagogastric junction. Inflammopharmacology, 2015, 23, 91-99.	1.9	5
222	Section Review: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Development of NSAIDs with reduced gastrointestinal and renal toxicity. Expert Opinion on Investigational Drugs, 1995, 4, 613-619.	1.9	4
223	Nitric oxide-releasing non-steroidal anti-inflammatory drugs: a new generation of antithrombotics?. Expert Opinion on Investigational Drugs, 1997, 6, 533-538.	1.9	4
224	Effect of Ketoprofen and ATBâ€352 on the Immature Human Intestine. Journal of Pediatric Gastroenterology and Nutrition, 2019, 68, 623-629.	0.9	4
225	Potent antiâ€inflammatory effects of an H ₂ Sâ€releasing naproxen (ATBâ€346) in a human model of inflammation. FASEB Journal, 2021, 35, e21913.	0.2	4
226	Inflammatory Bowel Disorders. BioDrugs, 1997, 7, 273-284.	2.2	3
227	Proteinase-activated receptors (PARs), platelets and angiogenesis. Drug Development Research, 2003, 59, 395-399.	1.4	3
228	Comment on â€œEvidence that the ProPerDP method is inadequate for protein persulfidation detection due to lack of specificityâ€• Science Advances, 2021, 7, .	4.7	3
229	From primordial gas to the medicine cabinet. British Journal of Pharmacology, 2020, 177, 715-719.	2.7	2
230	Hydrogen Sulfide: Its Production, Release and Functions. , 2013, , 109-125.		2
231	GI and Cardiovascular Profiles of New NSAIDs: Selective COX-2 Inhibitors and NO-NSAIDs. Medical Science Symposia Series, 2001, , 163-169.	0.0	2
232	Trends in development of gi-safe anti-inflammatory drugs. Klinicheskaia Meditsina, 2017, 95, 222-227.	0.2	2
233	Exploiting Endogenous Anti-Inflammatory Pathways as a Therapeutic Approach to Multiorgan Inflammatory Disease. American Journal of Pathology, 2014, 184, 2154-2155.	1.9	1
234	NSAID-Induced Gastrointestinal Damage and the Design of GI-Sparing NSAIDs. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, CL-24.	0.0	1

#	Article	IF	Citations
235	Inflammatory Mediators in Inflammatory Bowel Disease: Clues for Designer Therapy. Canadian Journal of Gastroenterology & Hepatology, 1993, 7, 121-126.	1.8	0
236	Effects of Râ€•and Sâ€enantiomers of chiral nonâ€steroidal antiâ€inflammatory drugs in experimental colitis. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, S266-S269.	1.4	0
237	Resolution of mucosal inflammation. , 2008, , 223-234.		0
238	Gastrointestinal Inflammation and Ulceration: Mediators of Induction and Resolution. , 0, , 282-298.		0
239	Efficacy of a Peruvian Botanical Remedy (Sabell A4+) for Treating Liver Disease and Protecting Gastric Mucosal Integrity. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-11.	0.5	0
240	HYDROGEN SULFIDE-RELEASING ANTI-INFLAMMATORY DRUG ATB-340 TREATMENT POTENTIALLY REDUCES MESENTERIC METAFLAMMATION IN THE EXPERIMENTAL AGE- AND HIGH FRUCTOSE DIETARY-INDUCED INJURY. Proceedings of the Shevchenko Scientific Society Medical Sciences, 2021, 64, .	0.0	0
241	The Arachidonic Acid Pathway. , 2000, , 1-20.		0
242	The vascular endothelium and nitric oxide. , 2004, , 13-18.		0
243	A Hydrogenâ€Sulfide Releasing Derivative of Mesalamine Exhibits Markedly Enhanced Antiâ€inflammatory Effects in Experimental Colitis. FASEB Journal, 2007, 21, A131.	0.2	0